Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

As Stacey Leasca reports for “Food & Wine,” research from Cornell University found that households with at least one GLP-1 ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Amycretin, a novel once-weekly subcutaneous GLP-1 and amylin receptor agonist, was safe compared with other incretin-based ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 results along with program updates, progress in its GLP-1 trials, a capital ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

Unlock the potential of GLP-1 therapies! Join experts to explore cutting-edge strategies for managing cardiovascular & ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.

Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

Telehealth company Hims & Hers is playing offense in a new commercial slated to air during the Super Bowl next month. | Telehealth company Hims & Hers is playing offense in a new commercial slated to ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...